+44 20 8123 2220
info@marketpublishers.com

Physician Views: Evaluating the Launch of Novartis' Cosentyx for Psoriasis

https://marketpublishers.com/r/P2FD4D0F96DEN.html
Date: June 2015
Pages: 0
Price: US$ 695.00 (Single User License)
ID: P2FD4D0F96DEN

Abstracts

Approved in both the US and EU at the beginning of the year, Novartis' first-to-market IL-17 inhibitor Cosentyx could be the most effective psoriasis treatment available, suggest key opinion leaders recently interviewed by FirstWord.

Novartis certainly appears confident in the commercial outlook for Cosentyx, indicating at an investor presentation last week that the monoclonal antibody could generate peak annual sales of between $4 billion and $5 billion (ViewPoints: As dust settles on brodalumab setback, Novartis touts Cosentyx as game-changer in psoriasis).

Currently being assessed in Phase III studies, Eli Lilly's competing IL-17 inhibitor ixekizumab will provide a competitive threat at some point in the future, as will a raft of other, earlier development-stage therapies assessed in FirstWord's forthcoming report on the psoriasis market.

It remains unclear as to whether a recently announced safety concern for another IL-17 inhibitor – AstraZeneca's brodalumab, which may or may not reach the market – will prove beneficial to Cosentyx or will heighten caution towards the class until long-term safety data is available.

With Cosentyx now available for some months, and with the product poised to be one of the biggest new drug approvals of 2015, FirstWord is polling dermatologists with the following questions...

> In your experience with Cosentyx (secukinumab) to date, how would you characterise efficacy?

+44 20 8123 2220
info@marketpublishers.com

In your experience with Cosentyx to date, how would you characterise safety/tolerability?

Over the next 12 months, how do you expect your usage of Cosentyx to change?

Have side-effect concerns with another development-stage anti 1L-17 antibody (brodalumab) had/will have any adverse impact on your usage of Cosentyx?

In 12 months' time, in what percentage of patients would you expect to be using Cosentyx as the first-line biologic therapy?

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Physician Views: Evaluating the Launch of Novartis' Cosentyx for Psoriasis
Product link: https://marketpublishers.com/r/P2FD4D0F96DEN.html
Price: US$ 695.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P2FD4D0F96DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970